Developer docs
API playgroundTry for free, no card

Search company profiles

OmniScience

Full company profile

uuid0005bv1

Namestring
OmniScience
Legal namestring
OmniScience, Inc.
Websiteurl
omniscience.bio
Company typeenum
Private
Founded yearint
2017
Descriptiontext

OmniScience, Inc. is a Houston, Texas-based AI platform company that builds and sells Vivo, an agentic AI-powered control tower for clinical development, to pharmaceutical sponsors, biotechnology companies, contract research organizations (CROs), and digital health and medical device firms. Founded in 2017 as a clinical data science consultancy originally operating under the name Mercury Data Science, the company rebranded to OmniScience in 2024 and pivoted from services to a product-led platform strategy with Vivo as its flagship offering. The stated footprint is 11–50 employees, a Houston headquarters in the Texas Medical Center Innovation district, and stated engagement with more than 50 life sciences organizations across hundreds of trials spanning Phases 1, 2, 3, and OLE in oncology, CNS, rare disease, and immunology.

Vivo is structured as a five-layer clinical trial intelligence architecture: (L1) Data Sources including EDC, CTMS, TMF, safety databases, labs, imaging, eCOA, IRT, wearables, biomarkers, omics, and vendor files; (L2) a unified, harmonized, governed, AI-ready, role-aware clinical trial data layer; (L3) an agentic reasoning layer that is protocol-aware, source-backed, explainable, role-aware, and blinding-enforced; (L4) a monitoring and evidence layer delivering AI-RBQM risk signals, issue tracking, and evidence packages; and (L5) an action layer that exposes Trial Home, Ask Vivo, workflow tools, APIs, and portfolio views. The architecture is read-only against source systems to preserve data integrity, and the platform is ISO 27001 and ISO 9001 certified, GDPR and HIPAA compliant, GxP-aligned, and built to FDA Part 11/Annex 11 and CSA guidance. The product surface includes Clinical Operations, Data Management and Biometrics, Safety and Medical Monitoring, Portfolio Leadership, CRO/FSP Partners, and Enterprise AI modules; AI capabilities span natural-language querying, multimodal data fusion (text, video, audio, structured, biosensor), anomaly detection, predictive analytics, and computer vision, with one licensed downstream application (tScreen by futuresTHRIVE) using Vivo for pediatric mental health screening.

OmniScience monetizes Vivo primarily through fixed annual enterprise subscription licenses covering all users within a study, with onboarding costs scaled to study complexity (duration, endpoints, data sources, geography) and portfolio-based pricing for multi-study deployments. Go-to-market combines direct enterprise field sales, event-driven demand generation at SCOPE, CNS Summit, DPHARM Idol Disrupt, and Innovation Network Gathering, and channel-led distribution through integration partnerships with Veeva (CTMS/TMF), Medidata (EDC), LabConnect (LIMS), TransCelerate BioPharma (membership), and developer/AI programs at NVIDIA Inception and Google Cloud AI Startups. The company highlights quantifiable outcomes including a 25% acceleration of database lock timelines, a 60–70% reduction in manual tasks, and most teams going live in 6–8 weeks; revenue figures, funding history beyond Mercury Fund incubation, and detailed customer counts are not publicly disclosed.

Short descriptiontext

OmniScience provides Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented trial data sources and delivers real-time, source-backed, role-aware insights to pharmaceutical sponsors, biotech companies, CROs, and digital health firms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersHouston, United States
HQ citystring
Houston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical trial intelligence, AI clinical trials, risk-based monitoring, clinical data platform, pharma AI software
Industry2 codes
PRIMARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGACAN
Site Quality Management & Audit Readiness
NAICS code2 codes
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Trial Intelligence Software
No data
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model1 record
1Vivo Platform Subscription
TypeSubscription Recurring
Description

Fixed annual license for Vivo platform access. Covers all users, hosting, maintenance, upgrades, and support. Onboarding costs based on study complexity (duration, endpoints, data sources, geography). Portfolio-based quotes available for multi-study deployments.

omniscience.bio
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Fixed annual license with study-based configuration
ModelSubscriptionBilling cadenceAnnual
Notes

Fixed annual license covers all users within a study. Onboarding costs are based on study complexity factors including duration, endpoints, data sources, and geography. Portfolio-based pricing available for multi-study deployments. License includes hosting, maintenance, upgrades, and support.

omniscience.bio
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1Vivo
Description

AI Control Tower for Clinical Development - the first agentic AI-powered control tower purpose-built for clinical trials, providing real-time, explainable insights by unifying clinical, safety, and operational data.

omniscience.bio
Core offering1 text field

OmniScience sells Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented clinical, safety, and operational data from EDC, CTMS, labs, imaging, eCOA, IRT, wearables, and vendor files into a single governed layer. The platform delivers real-time, source-backed answers (Ask Vivo), continuous AI-RBQM risk monitoring, live operational dashboards (Trial Home), and cross-study portfolio intelligence. It is sold to pharmaceutical sponsors, biotech companies, CROs, and digital health organizations under a fixed annual subscription license.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Database lock timelines accelerated by 25%
+3 more records
Product overview1 text field

OmniScience offers Vivo, a unified platform-plus-modules architecture for clinical trial intelligence. The core product is Vivo, an agentic AI-powered control tower built on a five-layer architecture that connects to clinical trial data sources, harmonizes them into a unified governed layer, applies agentic reasoning, monitors continuously for risks, and surfaces insights through multiple interfaces. Key interfaces include Ask Vivo (conversational AI for plain-language querying), Trial Home (live operational dashboard), AI-RBQM (continuous risk monitoring), and Portfolio Intelligence (cross-study visibility). These are available as integrated modules for Clinical Operations, Data Management & Biometrics, Safety & Medical Monitoring, CRO/FSP Partners, and Enterprise AI. Additionally, OmniScience's technology powers licensed applications such as tScreen for pediatric mental health screening.

Product and service8 records
1Vivo Platform
CategoryClinical Trial Intelligence Platform
Description

Vivo is an agentic AI-powered control tower for clinical development that unifies fragmented clinical, safety, and operational data from EDC, CTMS, labs, safety, imaging, eCOA, IRT, wearables, biomarkers, omics, and vendor files into a single governed, AI-ready data layer. It delivers real-time, source-backed answers, continuous AI-RBQM risk monitoring, and cross-study portfolio intelligence for pharmaceutical sponsors, biotech companies, CROs, and digital health organizations.

2Vivo Clinical Operations Solution
CategoryClinical Trial Intelligence Module
Description

A Vivo module for clinical operations teams managing active trials, providing earlier visibility into enrollment, site and vendor monitoring, fewer manual reports, and live operational status across studies.

3Vivo Data Management & Biometrics Solution
CategoryClinical Trial Intelligence Module
Description

A Vivo module for data managers and biometrics teams to find data issues earlier, prove readiness with traceable evidence, and progress from discrepancy through query, sign-off, to lock readiness with accelerated database lock.

4Vivo Safety & Medical Monitoring Solution
CategoryClinical Trial Intelligence Module
Description

A Vivo module for safety and medical monitoring teams to review safety signals in clinical context, connecting AEs, labs, conmeds, dose, and subject patterns with source-backed evidence for medical review.

5Vivo CRO & FSP Partners Solution
CategoryClinical Trial Intelligence Module
Description

A Vivo module giving sponsors transparency and CROs/FSP partners a shared evidence layer for delivery accountability and quality oversight across concurrent programs.

6Vivo Portfolio Intelligence
CategoryClinical Trial Intelligence Module
Description

Vivo Portfolio Intelligence provides cross-study visibility into risks, sites, vendors, enrollment, data quality, and executive priorities from one trial to an entire portfolio, with Portfolio Ask Vivo enabling source-backed questions across studies.

7Vivo Enterprise AI Solution
CategoryClinical Trial Intelligence Module
Description

A Vivo module for powering internal copilots, analytics workbenches, and agent ecosystems with governed, protocol-aware clinical trial intelligence, with API and headless deployment patterns for enterprise AI integration.

8tScreen (licensed Vivo-powered application)
CategoryLicensed Clinical Application
Description

tScreen is a licensed pediatric mental health screening application developed by futuresTHRIVE that leverages Vivo's voice and video analytics to monitor emotional state, language use, and mental health indicators in children aged 5-9, showing 87% agreement with PSC gold standard.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
1TransCelerate BioPharma
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-27
Description

Solution Collaboration Forum Member - joins global network of biopharma leaders, technology innovators, health authorities, and research organizations transforming clinical development. Contributes expertise in agentic AI, real-time clinical trial intelligence, and unified data infrastructure.

omniscience.bio
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-09-15
Description

LIMS Integration Partner - first agentic AI solution for real-time clinical trial lab insights. LabConnect provides clinical lab services; Vivo unifies lab data with other trial data sources for real-time insights.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-12
Description

Collaboration to improve cancer clinical study outcomes through enhanced image analysis and streamlined trial operations. Focus on breast and lung cancers initially, with expansion planned. Integro's fluorescent imaging agent for surgical visualization combined with OmniScience's AI-powered trial intelligence.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-04
Description

Partnership to accelerate INmune Bio's global Phase 2 Alzheimer's trial (AD02) using Vivo. Trial enrolled 208 patients (56% mild AD, 44% MCI). Vivo provides real-time analysis of cognitive results, identifies data discrepancies, and enables faster decision-making. INmune Bio provides continuous feedback that enables Vivo's product roadmap evolution.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-11-11
Description

futuresTHRIVE licensed Vivo for tScreen product - pediatric mental health screening for children aged 5-9. NSF-funded research collaboration since June 2022. Vivo's voice/video analytics capabilities analyze children's emotional state and language use for mental health assessment. tScreen showed 87% agreement with PSC gold standard.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-06
Description

Strategic partnership to advance digital endpoints in clinical trials. Contributes to DiMe's 'Building the Business Case for Digital Endpoints' initiative including industry benchmarking tools, ROI forecasting models, and business case templates. OmniScience provides AI platforms (Vivo, Ergo) for digital measure integration.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2022-02-01
Description

Collaborative work with Janssen Neuroscience team at ACNP Annual Meeting. Published poster abstracts on clinical subtypes and digital biomarker-based stratification in autism using EEG, ECG, and biosensors. Collaboration informed future clinical trial study designs.

Strategic tierMajorTypeTechnology or Integration
Description

NVIDIA Inception Program Member - AI innovation ecosystem providing technical enablement, GPU resources, and credibility for AI-powered clinical trial solutions.

Strategic tierMajorTypeTechnology or Integration
Description

Google Cloud AI Startups Program member - access to Google's global network to scale Vivo platform and reshape clinical development.

Strategic tierMajorTypeTechnology or Integration
Description

Member of Johnson & Johnson JLABS Incubator - early-stage innovation partnership providing access to J&J's ecosystem and validation for startups in the healthcare/life sciences space.

Strategic tierCoreTypeTechnology or Integration
Description

Integration with Veeva CTMS and TMF - delivering agentic AI insights across clinical trials. Vivo powers unified trial intelligence across Veeva's clinical trial management ecosystem.

Strategic tierMajorTypeTechnology or Integration
Description

Medidata Developer Central Member - EDC integration partnership enabling Vivo to connect with Medidata's electronic data capture systems.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Veeva provides CTMS, TMF, eTMF, and the broader Vault clinical suite; it is an OmniScience integration partner but also a deep incumbent in trial management technology whose roadmap could expand toward agentic AI.

TypeDirect peer
Description

Castor is a clinical trial data capture and eCRF platform with growing AI capabilities for trial operations. Its eCRF + integrations footprint competes with Vivo's data management and trial oversight modules for mid-size sponsor accounts.

TypeDirect peer
Description

CluePoints is the established leader in Risk-Based Quality Management (RBQM) and centralized statistical monitoring for clinical trials. OmniScience's AI-RBQM directly overlaps with CluePoints' core risk-based monitoring franchise.

TypeDirect peer
Description

Saama applies AI/ML to unify clinical, safety, and operational data for life sciences sponsors. It is the closest direct competitor to Vivo's agentic, unified-data layer for clinical development across pharma and biotech.

TypeDirect peer
Description

Cytel provides statistical programming, biostatistics, and clinical analytics software (including Solara) for clinical trial data. Its data-management and statistical programming capabilities overlap with OmniScience's Data Management & Biometrics module.

TypeBroad incumbent
Description

IQVIA is the largest CRO and life sciences technology vendor, with deep enterprise data and analytics assets. Its scale, installed base, and EDC/CTMS footprint make it the dominant broad incumbent competing for sponsor-level AI clinical intelligence spend.

TypeBroad incumbent
Description

Medidata is the leading EDC and clinical trial data platform (Rave) used by most large pharma sponsors. It is also an OmniScience integration partner (Medidata Developer Central), but its broader Rave, imaging, and AI ambitions overlap with the control tower value proposition.

TypeDirect peer
Description

THREAD provides a decentralized clinical trial technology platform supporting eCOA, telehealth, and digital health data capture. It overlaps with OmniScience on multimodal (DHT, video, sensor) clinical trial intelligence use cases.

TypeDirect peer
Description

YPrime offers eCOA, IRT, and clinical technology platforms used by pharma sponsors and CROs. It shares the trial-data integration and oversight category where OmniScience's unified data layer competes.

10Oracle Health Sciences
TypeBroad incumbent
Description

Oracle Health Sciences (formerly Phase Forward / InForm) provides EDC, CTMS, safety, and analytics for clinical development. Its broad clinical portfolio competes for the same sponsor budgets as OmniScience's unified clinical data layer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers15 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration3 records

Each record includes

Title, Type, Description, Source

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OmniScience

Clinical Trial Intelligence Softwareomniscience.bio

OmniScience provides Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented trial data sources and delivers real-time, source-backed, role-aware insights to pharmaceutical sponsors, biotech companies, CROs, and digital health firms.

What OmniScience does

OmniScience, Inc. is a Houston, Texas-based AI platform company that builds and sells Vivo, an agentic AI-powered control tower for clinical development, to pharmaceutical sponsors, biotechnology companies, contract research organizations (CROs), and digital health and medical device firms. Founded in 2017 as a clinical data science consultancy originally operating under the name Mercury Data Science, the company rebranded to OmniScience in 2024 and pivoted from services to a product-led platform strategy with Vivo as its flagship offering. The stated footprint is 11–50 employees, a Houston headquarters in the Texas Medical Center Innovation district, and stated engagement with more than 50 life sciences organizations across hundreds of trials spanning Phases 1, 2, 3, and OLE in oncology, CNS, rare disease, and immunology.

Vivo is structured as a five-layer clinical trial intelligence architecture: (L1) Data Sources including EDC, CTMS, TMF, safety databases, labs, imaging, eCOA, IRT, wearables, biomarkers, omics, and vendor files; (L2) a unified, harmonized, governed, AI-ready, role-aware clinical trial data layer; (L3) an agentic reasoning layer that is protocol-aware, source-backed, explainable, role-aware, and blinding-enforced; (L4) a monitoring and evidence layer delivering AI-RBQM risk signals, issue tracking, and evidence packages; and (L5) an action layer that exposes Trial Home, Ask Vivo, workflow tools, APIs, and portfolio views. The architecture is read-only against source systems to preserve data integrity, and the platform is ISO 27001 and ISO 9001 certified, GDPR and HIPAA compliant, GxP-aligned, and built to FDA Part 11/Annex 11 and CSA guidance. The product surface includes Clinical Operations, Data Management and Biometrics, Safety and Medical Monitoring, Portfolio Leadership, CRO/FSP Partners, and Enterprise AI modules; AI capabilities span natural-language querying, multimodal data fusion (text, video, audio, structured, biosensor), anomaly detection, predictive analytics, and computer vision, with one licensed downstream application (tScreen by futuresTHRIVE) using Vivo for pediatric mental health screening.

OmniScience monetizes Vivo primarily through fixed annual enterprise subscription licenses covering all users within a study, with onboarding costs scaled to study complexity (duration, endpoints, data sources, geography) and portfolio-based pricing for multi-study deployments. Go-to-market combines direct enterprise field sales, event-driven demand generation at SCOPE, CNS Summit, DPHARM Idol Disrupt, and Innovation Network Gathering, and channel-led distribution through integration partnerships with Veeva (CTMS/TMF), Medidata (EDC), LabConnect (LIMS), TransCelerate BioPharma (membership), and developer/AI programs at NVIDIA Inception and Google Cloud AI Startups. The company highlights quantifiable outcomes including a 25% acceleration of database lock timelines, a 60–70% reduction in manual tasks, and most teams going live in 6–8 weeks; revenue figures, funding history beyond Mercury Fund incubation, and detailed customer counts are not publicly disclosed.

OmniScience firmographics

Firmographics
Name
OmniScience
Legal name
OmniScience, Inc.
Website
https://omniscience.bio
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
OmniScience provides Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented trial data sources and delivers real-time, source-backed, role-aware insights to pharmaceutical sponsors, biotech companies, CROs, and digital health firms.
Ownership category
akta.pro rank

OmniScience industry classification

Industry
Product category
Clinical Trial Intelligence Software
NAICS
Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAOAB
Data Management, Biostatistics & Statistical Programming FSP
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Scientific Staffing & Functional Service Providers (FSP)
SECONDARYHLAGACAN
Site Quality Management & Audit Readiness

Keywords

  • Clinical trial intelligence
  • AI clinical trials
  • Risk-based monitoring
  • Clinical data platform
  • Pharma AI software

Where OmniScience is headquartered

Location

Headquarters

HQ city
Houston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OmniScience business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Vivo Platform Subscription: Fixed annual license for Vivo platform access. Covers all users, hosting, maintenance, upgrades, and support. Onboarding costs based on study complexity (duration, endpoints, data sources, geography). Portfolio-based quotes available for multi-study deployments.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualFixed annual license with study-based configuration

Go-to-market motion3 records

Distribution channels3 records

Marketing channels6 records

OmniScience product offering

Product offering

Core offering

OmniScience sells Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented clinical, safety, and operational data from EDC, CTMS, labs, imaging, eCOA, IRT, wearables, and vendor files into a single governed layer. The platform delivers real-time, source-backed answers (Ask Vivo), continuous AI-RBQM risk monitoring, live operational dashboards (Trial Home), and cross-study portfolio intelligence. It is sold to pharmaceutical sponsors, biotech companies, CROs, and digital health organizations under a fixed annual subscription license.

Product overview

OmniScience offers Vivo, a unified platform-plus-modules architecture for clinical trial intelligence. The core product is Vivo, an agentic AI-powered control tower built on a five-layer architecture that connects to clinical trial data sources, harmonizes them into a unified governed layer, applies agentic reasoning, monitors continuously for risks, and surfaces insights through multiple interfaces. Key interfaces include Ask Vivo (conversational AI for plain-language querying), Trial Home (live operational dashboard), AI-RBQM (continuous risk monitoring), and Portfolio Intelligence (cross-study visibility). These are available as integrated modules for Clinical Operations, Data Management & Biometrics, Safety & Medical Monitoring, CRO/FSP Partners, and Enterprise AI. Additionally, OmniScience's technology powers licensed applications such as tScreen for pediatric mental health screening.

Differentiator

Problem solved

Functional benefit

Brands

  • Vivo: AI Control Tower for Clinical Development - the first agentic AI-powered control tower purpose-built for clinical trials, providing real-time, explainable insights by unifying clinical, safety, and operational data.

Products and services

  • Vivo Platform Vivo is an agentic AI-powered control tower for clinical development that unifies fragmented clinical, safety, and operational data from EDC, CTMS, labs, safety, imaging, eCOA, IRT, wearables, biomarkers, omics, and vendor files into a single governed, AI-ready data layer. It delivers real-time, source-backed answers, continuous AI-RBQM risk monitoring, and cross-study portfolio intelligence for pharmaceutical sponsors, biotech companies, CROs, and digital health organizations.
  • Vivo Clinical Operations Solution A Vivo module for clinical operations teams managing active trials, providing earlier visibility into enrollment, site and vendor monitoring, fewer manual reports, and live operational status across studies.
  • Vivo Data Management & Biometrics Solution A Vivo module for data managers and biometrics teams to find data issues earlier, prove readiness with traceable evidence, and progress from discrepancy through query, sign-off, to lock readiness with accelerated database lock.
  • Vivo Safety & Medical Monitoring Solution A Vivo module for safety and medical monitoring teams to review safety signals in clinical context, connecting AEs, labs, conmeds, dose, and subject patterns with source-backed evidence for medical review.
  • Vivo CRO & FSP Partners Solution A Vivo module giving sponsors transparency and CROs/FSP partners a shared evidence layer for delivery accountability and quality oversight across concurrent programs.
  • Vivo Portfolio Intelligence Vivo Portfolio Intelligence provides cross-study visibility into risks, sites, vendors, enrollment, data quality, and executive priorities from one trial to an entire portfolio, with Portfolio Ask Vivo enabling source-backed questions across studies.
  • Vivo Enterprise AI Solution A Vivo module for powering internal copilots, analytics workbenches, and agent ecosystems with governed, protocol-aware clinical trial intelligence, with API and headless deployment patterns for enterprise AI integration.
  • tScreen (licensed Vivo-powered application) tScreen is a licensed pediatric mental health screening application developed by futuresTHRIVE that leverages Vivo's voice and video analytics to monitor emotional state, language use, and mental health indicators in children aged 5-9, showing 87% agreement with PSC gold standard.

Quantifiable outcome

  • Database lock timelines accelerated by 25%
  • +3 more outcomes

Companies that use OmniScience

Customer profile

Named customers15 records

Segments4 records

Ideal customer profiles4 records

OmniScience technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability13 records

Feature6 records

OmniScience partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core and major.

  • TransCelerate BioPharmacoreStrategic or Co-development Partner · 27 May 2026Solution Collaboration Forum Member - joins global network of biopharma leaders, technology innovators, health authorities, and research organizations transforming clinical development. Contributes expertise in agentic AI, real-time clinical trial intelligence, and unified data infrastructure.
  • LabConnectcoreTechnology or Integration · 15 September 2025LIMS Integration Partner - first agentic AI solution for real-time clinical trial lab insights. LabConnect provides clinical lab services; Vivo unifies lab data with other trial data sources for real-time insights.
  • Integro TheranosticscoreStrategic or Co-development Partner · 12 February 2025Collaboration to improve cancer clinical study outcomes through enhanced image analysis and streamlined trial operations. Focus on breast and lung cancers initially, with expansion planned. Integro's fluorescent imaging agent for surgical visualization combined with OmniScience's AI-powered trial intelligence.
  • INmune BiocoreStrategic or Co-development Partner · 4 December 2024Partnership to accelerate INmune Bio's global Phase 2 Alzheimer's trial (AD02) using Vivo. Trial enrolled 208 patients (56% mild AD, 44% MCI). Vivo provides real-time analysis of cognitive results, identifies data discrepancies, and enables faster decision-making. INmune Bio provides continuous feedback that enables Vivo's product roadmap evolution.
  • futuresTHRIVEcoreOEM/ Whitelabel/ Licensing Partner · 11 November 2024futuresTHRIVE licensed Vivo for tScreen product - pediatric mental health screening for children aged 5-9. NSF-funded research collaboration since June 2022. Vivo's voice/video analytics capabilities analyze children's emotional state and language use for mental health assessment. tScreen showed 87% agreement with PSC gold standard.
  • DiMe (Digital Medicine Society)coreStrategic or Co-development Partner · 6 June 2024Strategic partnership to advance digital endpoints in clinical trials. Contributes to DiMe's 'Building the Business Case for Digital Endpoints' initiative including industry benchmarking tools, ROI forecasting models, and business case templates. OmniScience provides AI platforms (Vivo, Ergo) for digital measure integration.
  • Janssen (Johnson & Johnson)majorStrategic or Co-development Partner · 1 February 2022Collaborative work with Janssen Neuroscience team at ACNP Annual Meeting. Published poster abstracts on clinical subtypes and digital biomarker-based stratification in autism using EEG, ECG, and biosensors. Collaboration informed future clinical trial study designs.
  • NVIDIAmajorTechnology or IntegrationNVIDIA Inception Program Member - AI innovation ecosystem providing technical enablement, GPU resources, and credibility for AI-powered clinical trial solutions.
  • Google CloudmajorTechnology or IntegrationGoogle Cloud AI Startups Program member - access to Google's global network to scale Vivo platform and reshape clinical development.
  • Johnson & Johnson JLABSmajorTechnology or IntegrationMember of Johnson & Johnson JLABS Incubator - early-stage innovation partnership providing access to J&J's ecosystem and validation for startups in the healthcare/life sciences space.
  • VeevacoreTechnology or IntegrationIntegration with Veeva CTMS and TMF - delivering agentic AI insights across clinical trials. Vivo powers unified trial intelligence across Veeva's clinical trial management ecosystem.
  • MedidatamajorTechnology or IntegrationMedidata Developer Central Member - EDC integration partnership enabling Vivo to connect with Medidata's electronic data capture systems.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

OmniScience competitors and assessment

Company assessment

Broad incumbents

  • Veeva Systems: Veeva provides CTMS, TMF, eTMF, and the broader Vault clinical suite; it is an OmniScience integration partner but also a deep incumbent in trial management technology whose roadmap could expand toward agentic AI.
  • IQVIA: IQVIA is the largest CRO and life sciences technology vendor, with deep enterprise data and analytics assets. Its scale, installed base, and EDC/CTMS footprint make it the dominant broad incumbent competing for sponsor-level AI clinical intelligence spend.
  • Medidata Solutions: Medidata is the leading EDC and clinical trial data platform (Rave) used by most large pharma sponsors. It is also an OmniScience integration partner (Medidata Developer Central), but its broader Rave, imaging, and AI ambitions overlap with the control tower value proposition.
  • Oracle Health Sciences: Oracle Health Sciences (formerly Phase Forward / InForm) provides EDC, CTMS, safety, and analytics for clinical development. Its broad clinical portfolio competes for the same sponsor budgets as OmniScience's unified clinical data layer.

Direct peers

  • Castor: Castor is a clinical trial data capture and eCRF platform with growing AI capabilities for trial operations. Its eCRF + integrations footprint competes with Vivo's data management and trial oversight modules for mid-size sponsor accounts.
  • CluePoints: CluePoints is the established leader in Risk-Based Quality Management (RBQM) and centralized statistical monitoring for clinical trials. OmniScience's AI-RBQM directly overlaps with CluePoints' core risk-based monitoring franchise.
  • Saama Technologies: Saama applies AI/ML to unify clinical, safety, and operational data for life sciences sponsors. It is the closest direct competitor to Vivo's agentic, unified-data layer for clinical development across pharma and biotech.
  • Cytel: Cytel provides statistical programming, biostatistics, and clinical analytics software (including Solara) for clinical trial data. Its data-management and statistical programming capabilities overlap with OmniScience's Data Management & Biometrics module.
  • THREAD: THREAD provides a decentralized clinical trial technology platform supporting eCOA, telehealth, and digital health data capture. It overlaps with OmniScience on multimodal (DHT, video, sensor) clinical trial intelligence use cases.
  • YPrime: YPrime offers eCOA, IRT, and clinical technology platforms used by pharma sponsors and CROs. It shares the trial-data integration and oversight category where OmniScience's unified data layer competes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

OmniScience compliance and trust

Trust signal

Compliance4 records

OmniScience financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OmniScience leadership team

Management profile

Number of profiles

Profiles7 records

OmniScience funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OmniScience M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OmniScience

What does OmniScience do?

OmniScience sells Vivo, an agentic AI-powered control tower for clinical development that unifies fragmented clinical, safety, and operational data from EDC, CTMS, labs, imaging, eCOA, IRT, wearables, and vendor files into a single governed layer. The platform delivers real-time, source-backed answers (Ask Vivo), continuous AI-RBQM risk monitoring, live operational dashboards (Trial Home), and cross-study portfolio intelligence. It is sold to pharmaceutical sponsors, biotech companies, CROs, and digital health organizations under a fixed annual subscription license.

Is OmniScience a public or private company?

OmniScience is a private company. It is classified as venture growth investor backed and is currently operating.

When was OmniScience founded?

OmniScience was founded in 2017. It employs 11 to 50 people.

Where is OmniScience based?

OmniScience is headquartered in Houston, United States, in the North America region.

How does OmniScience make money?

One revenue line is on record: vivo Platform Subscription.

Who are OmniScience's main competitors?

Broad incumbents on record are Veeva Systems, IQVIA, Medidata Solutions and Oracle Health Sciences. Direct peers are Castor, CluePoints, Saama Technologies, Cytel, THREAD and YPrime.

Does OmniScience have an API?

Yes. Vivo supports API and headless deployment patterns. The platform exposes Ask Vivo and monitoring outputs as APIs to power internal copilots, analytics workbenches, and reporting tools. Additionally, Vivo acts as a governed clinical domain agent within enterprise AI ecosystems and orchestration layers. API outputs feed into Trial Home, workflow tools, portfolio views, and enterprise agent systems.

What industry is OmniScience in?

OmniScience's product category is Clinical Trial Intelligence Software. Its primary akta.pro industry code is HLAGAOAB, Data Management, Biostatistics & Statistical Programming FSP, with a secondary code of HLAGACAN, Site Quality Management & Audit Readiness. Its NAICS code is 5132 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
OmniscienceThe OmniScience Board: A Track Record of Innovation and Commercial Success in Clinical TrialsLinda Blackerby and Nicola Marlin joined OmniScience's board in 2023, having previously worked together at Citeline. They discuss their shared mission to leverage AI for clinical trial efficiency and predict OmniScience will lead in agentic AI-driven trial operations.The Times of IndiaNifty to hit 31,000 by March 2027? OmniScience Capital is overweight on these sectors, but cautious on IT - The Economic TimesOmniScience Capital expects Nifty to trade in the 28,000-31,000 range by end of March 2027, representing a 15-25% upside from current levels, supported by estimated earnings growth of 10-13% for FY27. The investment management firm is overweight on banks, financial services, and the power sector while remaining cautious on IT stocks due to AI disruption uncertainty and limited near-to-medium term growth visibility. The positive outlook assumes easing geopolitical tensions, moderating crude oil prices, a strengthening rupee, and softer inflation that could enable the Reserve Bank of India to hold interest rates steady.Business StandardRs 50,000 monthly retirement income may need over Rs 1 cr in savings: StudyA study by OmniScience Capital found that achieving a monthly retirement income of Rs 50,000 in India requires a corpus ranging from Rs 1 crore to over Rs 2.3 crore, depending on the investment strategy adopted over a 40-year post-retirement horizon. The research compares four income-generation strategies—fixed deposits requiring Rs 2.30 crore, life annuities at Rs 2.35 crore, systematic withdrawal plans at Rs 1.60 crore, and a ScientificPay framework at Rs 1 crore. The findings highlight that retirement success depends less on the size of the corpus and more on how effectively investment structures manage inflation and longevity risks.Financial ExpressIs Rs 1 crore enough to retire in India? How long it may last in FD, SWP, annuity after adjusting for inflationA report by OmniScience Capital analyzes the viability of a Rs 1 crore retirement corpus in India through different strategies including Fixed Deposits, Life Annuity, Systematic Withdrawal Plans (SWP), and an equity-biased approach. It highlights that retirement success depends on managing inflation, longevity, and market risks, with each approach offering different trade-offs in sustainability. The report also estimates the amount of corpus needed relative to annual expenses for a sustainable retirement over 40 years.Financial ExpressIs Rs 1 crore enough to retire in India? How long it may last in FD, SWP, annuity after adjusting for inflationA new study by OmniScience Capital compares how long a Rs 1 crore retirement corpus may last in different investment strategies in India, considering inflation, longevity, and market risks. Conservative options like fixed deposits and life annuities risk depletion or declining purchasing power by age 70 or later, while an equity-based strategy could sustain income longer with higher volatility.Business TodayBanks, infra NBFCs, and power sector offer value amid market highs: Ashwini Shami of OmniScience CapitalAshwini Shami, President and Chief Portfolio Manager at OmniScience Capital, shared his investment outlook for Indian equity markets in 2026, noting that while the broader market is expensive at index level, selected sectors offer alpha opportunities at nearly 50% discount to current valuations. He identified Banks, HFCs, infrastructure NBFCs, and power sector as undervalued with strong growth outlook driven by infrastructure and private capex cycles, while cautioning that mid- and small-cap stocks are overvalued. Shami expects US Federal Reserve rate cuts of 50 basis points to boost FII inflows into India, supporting equity valuations and rupee stability.PR NewswireLabConnect und OmniScience stellen erste agentische KI-Lösung für Echtzeiterkenntnisse aus Labordaten klinischer Studien bereitLabConnect, a leading provider of central laboratory services, announced a strategic collaboration with OmniScience, the AI company behind Vivo, to launch the industry's first AI-powered solution enabling clinical trial sponsors to gain real-time insights from laboratory data. The partnership combines LabConnect's central testing and data management expertise with OmniScience's Vivo platform, allowing sponsors to consolidate fragmented lab datasets, automate monitoring, and detect risk signals. The collaboration aims to accelerate study timelines and improve outcomes by transforming static laboratory reports into dynamic, actionable information.PR NewswireLabConnect y OmniScience ofrecen la primera solución de IA de agentesLabConnect announced a strategic collaboration with OmniScience to offer the first AI agent-powered solution in the clinical trials sector, enabling sponsors to obtain real-time intelligent insights from clinical trial laboratory data. The partnership combines LabConnect's centralized laboratory analytics and data management expertise with OmniScience's Vivo AI platform, allowing sponsors to unify fragmented laboratory datasets, automate monitoring, and detect risk signals to accelerate trial timelines and improve outcomes. The collaboration underscores both organizations' commitment to innovation in clinical development by uniting LabConnect's technology-driven laboratory operations with OmniScience's native AI approach to clinical trial intelligence.PR NewswireLabConnect et OmniScience proposent la première solution d'IA agentique pour obtenir les données en temps réel de laboratoires d'essais cliniquesLabConnect announced a strategic collaboration with OmniScience to launch the first AI agentic solution in the clinical trial industry, enabling real-time intelligent insights from clinical trial laboratory data. The partnership combines LabConnect's central laboratory expertise with OmniScience's Vivo platform to unify fragmented laboratory datasets, automate oversight, and highlight risk signals to shorten trial timelines and improve outcomes. This collaboration represents both companies' commitment to innovation in clinical development, leveraging AI to transform static laboratory reports into actionable dynamic insights.PR NewswireLabConnect and OmniScience to Deliver First Agentic AI Solution for Real-Time Clinical Trial Lab InsightsLabConnect and OmniScience announced a strategic collaboration on September 15, 2025, to deliver the industry's first AI-driven solution enabling clinical trial sponsors to gain intelligent, real-time insights from lab data. The partnership combines LabConnect's central laboratory testing and data management expertise with OmniScience's Vivo agentic AI platform to unify fragmented lab datasets, automate oversight, and surface risk signals that accelerate trial timelines. Both companies emphasized their commitment to innovation in clinical development, aiming to transform lab results from static reports into dynamic, actionable intelligence to bring therapies to patients faster.